TABLE 3.
In vitro antiviral activity of SPD754 and marketed nucleoside reverse transcriptase inhibitors against clinical HIV-1 isolates of clades A to H
| Clade | No. of isolates | Mean IC50 ± SD (μM)a
|
||||||
|---|---|---|---|---|---|---|---|---|
| SPD754 | Zidovudine | Lamivudine | Didanosine | Zalcitabine | Stavudine | Abacavir | ||
| HIV-1IIIB | 26 | 0.023 ± 0.020 | 0.8 ± 0.3 | 1.6 ± 0.2 | 0.4 ± 0.1 | 1.1 ± 0.5 | 2.9 ± 2.3 | |
| CRF02_AG | 4 | 29 ± 15 | 0.033 ± 0.014 | 1.3 ± 0.8 | 1.4 ± 0.4 | 0.9 ± 0.3 | 1.6 ± 0.4 | 2.8 ± 1.1 |
| B | 4b | 27 ± 18 | 0.019 ± 0.013 | > 8.2 ± 15 | 1.4 ± 1.5 | 0.6 ± 0.7 | 0.8 ± 0.5 | 2.3 ± 1.6 |
| C | 4 | 23 ± 12 | 0.030 ± 0.021 | 0.5 ± 0.2 | 1.1 ± 0.8 | 0.5 ± 0.2 | 0.8 ± 0.1 | 1.4 ± 0.5 |
| D | 2 | 14 ± 4.8 | 0.016 ± 0.008 | 0.9 ± 0.7 | 1.4 ± 1.1 | 1.0 ± 1.0 | 0.9 ± 0.6 | 2.7 ± 2.6 |
| CRF01_AE | 4 | 30 ± 9.8 | 0.040 ± 0.030 | 1.3 ± 0.7 | 1.4 ± 0.7 | 0.3 ± 0.1 | 0.7 ± 0.3 | 1.7 ± 0.8 |
| CRF05_DF | 2 | 16 ± 11 | 0.042 ± 0.021 | 0.5 ± 0.1 | 0.8 ± 0.3 | 0.2 ± 0.0 | 0.7 ± 0.0 | 2.4 ± 0.7 |
| F | 1 | 47 | 0.015 | 1.9 | 0.8 | 1.1 | 0.6 | 1.5 |
| H | 2b | 21 ± 15 | 0.013 ± 0.0002 | >16 ± 22 | 2.5 ± 2.7 | 0.2 ± 0.0 | 1.2 ± 0.9 | 1.9 ± 1.1 |
a
IC50 values represent the results of duplicate assays.
b
Both of these groups contained one lamivudine-resistant isolate.